Patent · US Active

Compounds and methods for inhibiting the interaction of BCL proteins with binding partners

US7928244B2 · kind B2 · utility

0Cited by
4References
37Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 21, 2007
Grant dateApr 19, 2011
Priority date
Expiry dateFeb 15, 2030

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.